rawfin.tv
Novavax Shifts Focus to Partnership Model, Citing Sanofi and Pfizer Catalysts for Matrix-M Platform
MarketsstocksAI Generated

Novavax Shifts Focus to Partnership Model, Citing Sanofi and Pfizer Catalysts for Matrix-M Platform

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Novavax is reorienting its business strategy from COVID-19 vaccines to a partnership-driven model centered on its Matrix-M adjuvant technology. The company highlighted potential catalysts from collaborations with Sanofi and Pfizer.

NVAXPharmaceuticalsVaccinesPartnershipsBiotechHealthcare Sector

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks